Trials / Completed
CompletedNCT01842893
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
Randomized, Placebo-controlled Study of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Ethypharm · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fentanyl Ethypharm | After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo) |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2013-04-30
- Last updated
- 2013-05-03
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT01842893. Inclusion in this directory is not an endorsement.